Literature DB >> 16635425

Unraveling molecular markers of biologic therapies in glioma.

Andrew B Lassman, Lauren E Abrey.   

Abstract

Entities:  

Year:  2006        PMID： 16635425     DOI： 10.1007/s11910-006-0003-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  8 in total

1.  Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

Authors:  Andrew B Lassman; Michael R Rossi; Jeffrey J Raizer; Jeffrey R Razier; Lauren E Abrey; Frank S Lieberman; Chelsea N Grefe; Kathleen Lamborn; William Pao; Alan H Shih; John G Kuhn; Richard Wilson; Norma J Nowak; John K Cowell; Lisa M DeAngelis; Patrick Wen; Mark R Gilbert; Susan Chang; W A Yung; Michael Prados; Eric C Holland
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

2.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

Review 3.  Molecular biology of gliomas.

Authors:  Andrew B Lassman
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

4.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Authors:  Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

5.  Phase II trial of gefitinib in recurrent glioblastoma.

Authors:  Jeremy N Rich; David A Reardon; Terry Peery; Jeannette M Dowell; Jennifer A Quinn; Kara L Penne; Carol J Wikstrand; Lauren B Van Duyn; Janet E Dancey; Roger E McLendon; James C Kao; Timothy T Stenzel; B K Ahmed Rasheed; Sandra E Tourt-Uhlig; James E Herndon; James J Vredenburgh; John H Sampson; Allan H Friedman; Darell D Bigner; Henry S Friedman
Journal:  J Clin Oncol       Date:  2003-11-24       Impact factor: 44.544

6.  Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Authors:  Frederick F Lang; Mark R Gilbert; Vinay K Puduvalli; Jeffrey Weinberg; Victor A Levin; W K Alfred Yung; Raymond Sawaya; Gregory N Fuller; Charles A Conrad
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300

7.  KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

Authors:  William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold E Varmus
Journal:  PLoS Med       Date:  2005-01-25       Impact factor: 11.069

8.  Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

Authors:  Y Kokubo; A Gemma; R Noro; M Seike; K Kataoka; K Matsuda; T Okano; Y Minegishi; A Yoshimura; M Shibuya; S Kudoh
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.